Factoring in Safety Considerations With IV Iron Products

Panelists discuss how black box warnings on IV iron products, particularly regarding hypersensitivity reactions, influence their risk assessment, patient selection, monitoring protocols, and facility requirements for administration, while emphasizing that modern formulations have significantly improved safety profiles compared with older products.

EP: 1.Background and Causes of Iron Deficiency Anemia

EP: 2.Pathophysiology of Iron Deficiency Anemia

EP: 3.Symptoms and Epidemiology of Iron Deficiency Anemia

EP: 4.Diagnosis and Common Comorbidities Seen With Iron Deficiency Anemia

EP: 5.Monitoring Patients With Iron Deficiency Anemia After Diagnosis

EP: 6.Oral vs IV Iron in Clinical Practice

EP: 7.FDA-Approved IV Iron Formulations

Now Viewing

EP: 8.Factoring in Safety Considerations With IV Iron Products

EP: 9.Adverse Effects Associated With Hypophosphatemia

Video content above is prompted by the following:

• How does the presence of a black box warning on certain IV iron products influence your clinical decision-making process?

Related Videos

Related Content

Advertisement

February 5th 2025

Physician Gaps in Genetic Testing Knowledge May Impact Ovarian Cancer Care

Brooke McCormick

While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient access to genetic counseling.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

February 3rd 2025

Olaparib Leads PARP Inhibitors in Boosting OS for Platinum-Sensitive Recurrent Ovarian Cancer

Brooke McCormick

While all poly ADP-ribose polymerase (PARP) inhibitors improved progression-free survival, olaparib significantly extended overall survival (OS), making it a preferred option.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

January 31st 2025

Patient Care Experience Declines After Private Equity Hospital Acquisitions

Brooke McCormick

Private equity hospital acquisitions in the US were associated with declines in patient care experience, particularly in overall hospital ratings, willingness to recommend, and staff responsiveness.

January 31st 2025

FDA Quietly Removes Draft Guidance on Diversity in Clinical Trials Following Executive Order on DEI

Giuliana Grossi

The FDA removed previously issued draft guidance on diversity in clinical trials from its website without public notice or explanation.

Related Content

Advertisement

February 5th 2025

Physician Gaps in Genetic Testing Knowledge May Impact Ovarian Cancer Care

Brooke McCormick

While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient access to genetic counseling.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

February 3rd 2025

Olaparib Leads PARP Inhibitors in Boosting OS for Platinum-Sensitive Recurrent Ovarian Cancer

Brooke McCormick

While all poly ADP-ribose polymerase (PARP) inhibitors improved progression-free survival, olaparib significantly extended overall survival (OS), making it a preferred option.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

January 31st 2025

Patient Care Experience Declines After Private Equity Hospital Acquisitions

Brooke McCormick

Private equity hospital acquisitions in the US were associated with declines in patient care experience, particularly in overall hospital ratings, willingness to recommend, and staff responsiveness.

January 31st 2025

FDA Quietly Removes Draft Guidance on Diversity in Clinical Trials Following Executive Order on DEI

Giuliana Grossi

The FDA removed previously issued draft guidance on diversity in clinical trials from its website without public notice or explanation.